• français
    • English
  • English 
    • français
    • English
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.
BIRD Home

Browse

This CollectionBy Issue DateAuthorsTitlesSubjectsJournals BIRDResearch centres & CollectionsBy Issue DateAuthorsTitlesSubjectsJournals

My Account

Login

Statistics

View Usage Statistics

Economic evaluation of meningococcal vaccines: considerations for the future

Thumbnail
Date
2020
Dewey
Economie sociale
Sujet
Cost-effectiveness; Meningitis; Meningococcal; QALY; Vaccine
JEL code
I.I1.I18
Journal issue
The European Journal of Health Economics
Volume
21
Publication date
2020
Article pages
297-309
Publisher
Springer
DOI
http://dx.doi.org/10.1007/s10198-019-01129-z
URI
https://basepub.dauphine.fr/handle/123456789/21542
Collections
  • LEDa : Publications
Metadata
Show full item record
Author
Christensen, Hannah
545763 Bristol Renal, Bristol Medical School
Al-Janabi, Hareth
164366 Department of Economics
Lévy, Pierre
163517 Laboratoire d'Economie et de Gestion des Organisations de Santé [Legos]
559342 Laboratoire d'Economie de Dauphine [LEDa]
Postma, Maarten J.
1021737 FACULTY OF ECONOMICS UNIVERSITY OF GRONINGEN PAYS- BAS NLD
Bloom, David E.
199325 Department of Society, Human Development, and Health, Harvard School of Public Health, Boston
Landa, Paolo
460277 University of Exeter Medical School
Salisbury, David M.
Diez-Domingo, Javier
554767 Unit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Burjassot, Valencia, Spain
Towse, Adrian K.
Lorgelly, Paula K.
Shah, Koonal K.
Hernandez-Villafuerte, Karla
480809 Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Smith, Vinny
Glennie, Linda
Wright, Claire
York, Laura
Farkouh, Raymond
150695 Pfizer Inc
Type
Article accepté pour publication ou publié
Abstract (EN)
In 2018, a panel of health economics and meningococcal disease experts convened to review methodologies, frameworks, and decision-making processes for economic evaluations of vaccines, with a focus on evaluation of vaccines targeting invasive meningococcal disease (IMD). The panel discussed vaccine evaluation methods across countries; IMD prevention benefits that are well quantified using current methods, not well quantified, or missing in current cost-effectiveness methodologies; and development of recommendations for future evaluation methods. Consensus was reached on a number of points and further consideration was deemed necessary for some topics. Experts agreed that the unpredictability of IMD complicates an accurate evaluation of meningococcal vaccine benefits and that vaccine cost-effectiveness evaluations should encompass indirect benefits, both for meningococcal vaccines and vaccines in general. In addition, the panel agreed that transparency in the vaccine decision-making process is beneficial and should be implemented when possible. Further discussion is required to ascertain: how enhancing consistency of frameworks for evaluating outcomes of vaccine introduction can be improved; reviews of existing tools used to capture quality of life; how indirect costs are considered within models; and whether and how the weighting of quality-adjusted life-years (QALY), application of QALY adjustment factors, or use of altered cost-effectiveness thresholds should be used in the economic evaluation of vaccines.

  • Accueil Bibliothèque
  • Site de l'Université Paris-Dauphine
  • Contact
SCD Paris Dauphine - Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16

 Content on this site is licensed under a Creative Commons 2.0 France (CC BY-NC-ND 2.0) license.